KIMS warrants: ₹600 crore promoter infusion deal, 2026

Key announcement from the board

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) said its Board has approved raising about ₹600 crore through a preferential issue of warrants to promoter and promoter group entities. The proposal involves issuing 77,02,182 warrants, each convertible into one fully paid-up equity share. The issue price has been set at ₹779 per warrant against an equity face value of ₹2. KIMS stated the total consideration for the issuance is ₹599.9999778 crore (₹59,999.99 lakh), commonly rounded to ₹600 crore. The company will move ahead only after receiving shareholder and other required approvals.

What the preferential allotment includes

The instruments approved are warrants, not immediate equity shares. Each warrant is convertible into one equity share, which means the equity base can expand if and when warrants are exercised. KIMS disclosed that warrant holders can exercise conversion in one or more tranches. The conversion tenure is 18 months from the date of allotment. If warrants are not exercised within this period, the entitlement lapses and the amount paid upfront is forfeited, as per the terms shared by the company.

Price, premium, and regulatory basis

KIMS set the warrant price at ₹779 per unit, which includes a premium of ₹777 over the ₹2 face value. The company said the issue price has been determined in line with Regulation 164 of the SEBI ICDR Regulations and its articles of association. It also cited a valuation report from a registered valuer as part of the pricing process. The relevant date used for determining the issue price was June 9, 2026. These details matter because preferential pricing and allotments are closely governed under SEBI rules.

Who gets the warrants: promoter allocation details

The warrants are proposed to be allotted to two promoters and one promoter group entity. The allottees named by the company are Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. Dr. Abhinay Bollineni and Mr. Adwik Bollineni will receive 32,09,242 warrants each, while Bharas Ventures LLP will receive 12,83,698 warrants. In aggregate, the allocation totals 77,02,182 warrants for ₹599.9999778 crore.

Note: Aggregate consideration values are converted from the disclosed rupee amounts and rounded to two decimals. Total consideration disclosed by the company is ₹599.9999778 crore.

Payment schedule and conversion window

KIMS said subscribers must pay 25% of the issue price at the time of subscription. The remaining 75% is payable at the time of conversion into equity shares. The warrants can be exercised in one or more tranches during the 18-month tenure from the allotment date. If the warrants are not converted within this period, the initial payment will be forfeited. These terms are standard for preferential warrant issues and are designed to ensure conversion discipline.

Approvals pending and EGM date

The company has scheduled an Extraordinary General Meeting (EGM) for July 09, 2026 to seek shareholder consent for the preferential allotment. KIMS also approved the draft notice for the EGM and indicated that the meeting will be conducted via video conferencing. The preferential issue is also subject to other regulatory approvals, as applicable. The sequence is important for investors because the board approval alone does not complete a preferential allotment.

Why KIMS is raising money this way

KIMS framed the fund raise as a step to bolster its capital base. The company also indicated that the fundraising could support future expansion or operational requirements. Because the allotment is being made to promoters and the promoter group, the move is often read as a signal of promoter commitment. At the same time, warrants are a deferred equity instrument, so the full equity impact materialises only upon conversion.

Dilution risk and promoter holding context

KIMS cautioned that conversion of warrants into equity shares within 18 months can increase the total number of outstanding shares. That could dilute existing shareholders’ ownership percentage. Separately, the disclosure included details on current promoter holdings: promoter and promoter group holding stands at 13,64,89,330 shares, representing 34.11% of the company. Out of this, 1,40,00,000 shares are pledged, accounting for 3.50% of the total shareholding. One report included in the provided context also stated that if all warrants are converted, promoter group holding could rise from 34.11% to about 35.35% on a fully diluted basis.

Other governance and disclosure points

KIMS said its promoter group has not created any new encumbrances on shares during the financial year ended March 31, 2026. The company also noted that the trading window for designated persons and their immediate relatives remains closed until 48 hours after the conclusion of the board meeting. These are standard compliance disclosures under SEBI listing rules, but they provide context on insider trading controls around price-sensitive decisions.

Summary of key terms

The preferential issue is straightforward in structure: a fixed number of warrants at a fixed price, convertible into equity within a defined window. The key variable for minority shareholders is the extent and timing of conversions, which will determine eventual dilution.

Market impact and what to watch next

The immediate market implication from the disclosed details is the potential for equity dilution if and when the warrants are converted into shares. The other clear signal is promoter participation, since the allotment is entirely to promoters and a promoter group entity at a disclosed price determined under SEBI rules. For existing investors, the next confirmed event is the July 09, 2026 EGM where shareholder approval will be sought. After that, the timeline will depend on allotment formalities and any subsequent disclosures on tranche-wise conversion during the 18-month period.